SAGE
Income statement / Annual
Last year (2023), Sage Therapeutics, Inc.'s total revenue was $86.46 M,
an increase of 1,024.84% from the previous year.
In 2023, Sage Therapeutics, Inc.'s net income was -$541.49 M.
See Sage Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$86.46 M
|
$7.69 M
|
$6.31 M
|
$1.11 B
|
$6.87 M
|
$90.27 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$2.16 M |
$813,000.00 |
$553,000.00 |
$565,000.00 |
$400,000.00 |
$1.10 M |
$500,000.00 |
$281,000.00 |
$115,000.00 |
$0.00 |
| Gross Profit |
$84.30 M |
$6.87 M |
$5.76 M |
$1.11 B |
$6.47 M |
$89.17 M |
-$500,000.00 |
-$281,000.00 |
-$115,000.00 |
$0.00 |
| Gross Profit Ratio |
0.98 |
0.89 |
0.91 |
1 |
0.94 |
0.99 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$356.24 M
|
$326.16 M
|
$283.17 M
|
$292.71 M
|
$368.82 M
|
$282.11 M
|
$210.28 M
|
$120.76 M
|
$69.36 M
|
$24.10 M
|
| General & Administrative
Expenses |
$274.52 M
|
$227.70 M
|
$183.50 M
|
$196.95 M
|
$345.78 M
|
$201.40 M
|
$62.88 M
|
$39.41 M
|
$25.29 M
|
$9.71 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$44.60 M
|
$11.18 M
|
$5.27 M
|
$3.08 M
|
$0.00
|
| Selling, General &
Administrative Expenses |
$274.52 M
|
$227.70 M
|
$183.50 M
|
$196.95 M
|
$345.78 M
|
$201.40 M
|
$62.88 M
|
$39.41 M
|
$25.29 M
|
$9.71 M
|
| Other Expenses |
-$383,000.00 |
$15,000.00 |
$134,000.00 |
$250,000.00 |
$82,000.00 |
$22,000.00 |
-$64,000.00 |
-$35,000.00 |
-$23,000.00 |
-$9,000.00 |
| Operating Expenses |
$630.76 M |
$553.86 M |
$466.66 M |
$489.67 M |
$714.59 M |
$483.51 M |
$273.16 M |
$160.16 M |
$94.65 M |
$33.81 M |
| Cost And Expenses |
$632.92 M |
$554.68 M |
$467.22 M |
$490.23 M |
$714.99 M |
$483.51 M |
$273.16 M |
$160.16 M |
$94.65 M |
$33.81 M |
| Interest Income |
$38.74 M |
$14.19 M |
$2.88 M |
$9.60 M |
$27.80 M |
$20.33 M |
$3.10 M |
$1.21 M |
$178,000.00 |
$8,000.00 |
| Interest Expense |
$0.00 |
$14.19 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$8,000.00 |
| Depreciation &
Amortization |
$1.39 M
|
$1.12 M
|
$4.18 M
|
$2.63 M
|
$2.28 M
|
$1.10 M
|
$500,000.00
|
$281,000.00
|
$115,000.00
|
$51,000.00
|
| EBITDA |
-$511.68 M
|
-$546.99 M
|
-$460.91 M
|
$651.71 M
|
-$708.12 M
|
-$393.24 M
|
-$273.16 M
|
-$160.16 M
|
-$94.65 M
|
-$33.81 M
|
| EBITDA Ratio |
-5.92 |
-71.17 |
-73.07 |
0.58 |
-103.1 |
-4.36 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-6.71
|
-71.17
|
-73.07
|
0.54
|
-103.1
|
-4.36
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$33.77 M
|
$14.21 M
|
$3.02 M
|
$9.85 M
|
$27.89 M
|
$22,000.00
|
-$64,000.00
|
-$35,000.00
|
-$23,000.00
|
-$9,000.00
|
| Income Before Tax |
-$541.49 M |
-$532.78 M |
-$457.89 M |
$606.07 M |
-$680.24 M |
-$372.88 M |
-$270.12 M |
-$158.99 M |
-$94.50 M |
-$33.81 M |
| Income Before Tax Ratio
|
-6.26
|
-69.32
|
-72.59
|
0.54
|
-99.04
|
-4.13
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$5.36 M |
-$29.52 M |
-$7.07 M |
$15.52 M |
-$30.09 M |
$20.36 M |
-$3.63 M |
-$1.49 M |
-$293,000.00 |
-$59,000.00 |
| Net Income |
-$541.49 M |
-$503.27 M |
-$450.83 M |
$606.07 M |
-$650.15 M |
-$372.88 M |
-$270.12 M |
-$158.99 M |
-$94.50 M |
-$33.81 M |
| Net Income Ratio |
-6.26 |
-65.48 |
-71.47 |
0.54 |
-94.66 |
-4.13 |
0 |
0 |
0 |
0 |
| EPS |
-9.05 |
-8.49 |
-7.68 |
11.66 |
-12.79 |
-8.08 |
-7.09 |
-4.75 |
-3.4 |
-1.57 |
| EPS Diluted |
-9.05 |
-8.49 |
-7.68 |
11.43 |
-12.79 |
-8.08 |
-7.09 |
-4.75 |
-3.4 |
-1.57 |
| Weighted Average Shares
Out |
$59.84 M
|
$59.31 M
|
$58.67 M
|
$51.98 M
|
$50.83 M
|
$46.12 M
|
$38.10 M
|
$33.47 M
|
$27.78 M
|
$21.57 M
|
| Weighted Average Shares
Out Diluted |
$59.84 M
|
$59.31 M
|
$58.67 M
|
$53.00 M
|
$50.83 M
|
$46.12 M
|
$38.11 M
|
$33.49 M
|
$27.78 M
|
$21.57 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
